Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

On Pre-emption, OTC Rule Among Signs Tipping Obama Administration’s Hand

This article was originally published in The Tan Sheet

Executive Summary

FDA has not altered its support of pre-emption in product liability suits but there are signs it will happen under the Obama administration

You may also be interested in...



In Brief

FDA clarifies pre-emption on OTC labeling

In Brief

FDA clarifies pre-emption on OTC labeling

Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy

The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel